Sheldon Sloan

1.9k total citations · 1 hit paper
46 papers, 1.4k citations indexed

About

Sheldon Sloan is a scholar working on Surgery, Gastroenterology and Genetics. According to data from OpenAlex, Sheldon Sloan has authored 46 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Surgery, 25 papers in Gastroenterology and 15 papers in Genetics. Recurrent topics in Sheldon Sloan's work include Gastroesophageal reflux and treatments (24 papers), Helicobacter pylori-related gastroenterology studies (19 papers) and Inflammatory Bowel Disease (14 papers). Sheldon Sloan is often cited by papers focused on Gastroesophageal reflux and treatments (24 papers), Helicobacter pylori-related gastroenterology studies (19 papers) and Inflammatory Bowel Disease (14 papers). Sheldon Sloan collaborates with scholars based in United States, Belgium and Canada. Sheldon Sloan's co-authors include Peter J. Kahrilas, Alfred Rademaker, Christina Farup, Leah Kleinman, Dara Ganoczy, Dennis A. Revicki, Elsbeth Chee, Clara Lee, Philip B. Miner and Leonard Jokubaitis and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Sheldon Sloan

40 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

2023 190 citations William J. Sandborn, Séverine Vermeire et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheldon Sloan United States	13	1.1k	1.0k	200	188	130	46	1.4k
Lúther Sigurðsson United States	15	348 0.3×	827 0.8×	28 0.1×	37 0.2×	140 1.1×	32	1.3k
Michael Molloy‐Bland United Kingdom	10	297 0.3×	343 0.3×	32 0.2×	29 0.2×	67 0.5×	10	618
Fabio Panetta Italy	12	241 0.2×	194 0.2×	25 0.1×	120 0.6×	111 0.9×	25	474
Eduardo Moreno‐Osset Spain	15	189 0.2×	455 0.4×	28 0.1×	430 2.3×	402 3.1×	49	874
P. Usai Italy	10	785 0.7×	468 0.5×	8 0.0×	202 1.1×	524 4.0×	18	948
Maria Fotoulaki Greece	16	145 0.1×	261 0.3×	26 0.1×	65 0.3×	144 1.1×	52	618
P. Molteni Italy	11	257 0.2×	313 0.3×	13 0.1×	211 1.1×	207 1.6×	24	674
Ronald E. Pruitt United States	11	178 0.2×	443 0.4×	12 0.1×	429 2.3×	335 2.6×	29	993
B. Papadatou Italy	15	81 0.1×	228 0.2×	25 0.1×	314 1.7×	238 1.8×	48	661
Nitin K. Ahuja United States	15	242 0.2×	460 0.4×	68 0.3×	21 0.1×	31 0.2×	61	688

Countries citing papers authored by Sheldon Sloan

Since Specialization

Citations

This map shows the geographic impact of Sheldon Sloan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheldon Sloan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheldon Sloan more than expected).

Fields of papers citing papers by Sheldon Sloan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheldon Sloan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheldon Sloan. The network helps show where Sheldon Sloan may publish in the future.

Co-authorship network of co-authors of Sheldon Sloan

This figure shows the co-authorship network connecting the top 25 collaborators of Sheldon Sloan. A scholar is included among the top collaborators of Sheldon Sloan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheldon Sloan. Sheldon Sloan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sandborn, William J., Séverine Vermeire, Laurent Peyrin‐Biroulet, et al.. (2023). Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. The Lancet. 401(10383). 1159–1171. 190 indexed citations breakdown →

Gineste, Paul, Didier Scherrer, Josianne Nitcheu, et al.. (2023). S1097 Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks. The American Journal of Gastroenterology. 118(10S). S836–S836. 1 indexed citations

Wang, Yi‐Ting, Rupa Makadia, Jill Hardin, et al.. (2021). Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterology. 21(1). 121–121. 1 indexed citations

Danese, Silvio, Séverine Vermeire, Geert D’Haens, et al.. (2021). 105 CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL. Gastroenterology. 160(6). S–25. 4 indexed citations

Marini, Joseph C., et al.. (2019). P049 COMPARISON OF USTEKINUMAB CONCENTRATION ASSAYS AND ANTIBODIES-TO-USTEKINUMAB ASSAYS. Gastroenterology. 156(3). S35–S35.

Marini, Joseph C., et al.. (2019). P049 COMPARISON OF USTEKINUMAB CONCENTRATION ASSAYS AND ANTIBODIES-TO-USTEKINUMAB ASSAYS. Inflammatory Bowel Diseases. 25(Supplement_1). S24–S25. 1 indexed citations

Weinstein, Rachel, Daniel Fife, Sheldon Sloan, Erica A. Voss, & William R. Treem. (2015). Prevalence of Chronic Metoclopramide Use and Associated Diagnoses in the US Pediatric Population. Pediatric Drugs. 17(4). 331–337. 5 indexed citations

Hussain, Sunny Z., et al.. (2013). Safety and Efficacy of Delayed Release Rabeprazole in 1‐ to 11‐Month‐Old Infants With Symptomatic GERD. Journal of Pediatric Gastroenterology and Nutrition. 58(2). 226–236. 19 indexed citations

Gerson, Lauren B., George Triadafilopoulos, Peyman Sahbaie, et al.. (2008). Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. BMC Gastroenterology. 8(1). 15–15. 3 indexed citations

10.

Kahrilas, Peter J., Philip B. Miner, John F. Johanson, et al.. (2005). Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease. Digestive Diseases and Sciences. 50(11). 2009–2018. 37 indexed citations

11.

Sloan, Sheldon. (2003). Rabeprazole-Based Therapy in The Management of Symptomatic Gastroesophageal Reflux Disease. The American Journal of Gastroenterology. 98(3 Suppl). S49–S55. 6 indexed citations

12.

Damiano, Anne M., et al.. (2003). Reductions in Symptom Distress Reported by Patients with Moderately Severe, Nonerosive Gastroesophageal Reflux Disease Treated with Rabeprazole. Digestive Diseases and Sciences. 48(4). 657–662. 21 indexed citations

13.

Ricci, Judith A., et al.. (2002). Quality of Life in a US National Sample of Adults with Diabetes and Motility-Related Upper Gastrointestinal Symptoms. Digestive Diseases and Sciences. 47(4). 683–689. 9 indexed citations

14.

Miner, Philip B., et al.. (2002). Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. The American Journal of Gastroenterology. 97(6). 1332–1339. 128 indexed citations

15.

Farup, Christina, Leah Kleinman, Sheldon Sloan, et al.. (2001). The Impact of Nocturnal Symptoms Associated With Gastroesophageal Reflux Disease on Health-Related Quality of Life. Archives of Internal Medicine. 161(1). 45–45. 257 indexed citations

16.

Rentz, Anne M., Carmelina Battista, Elyse Trudeau, et al.. (2001). Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies. PharmacoEconomics. 19(4). 349–363. 44 indexed citations

17.

Frank, Lori, Leah Kleinman, Dara Ganoczy, et al.. (2000). Upper Gastrointestinal Symptoms in North America. Digestive Diseases and Sciences. 45(4). 809–818. 140 indexed citations

18.

Camacho, Fernando, et al.. (2000). Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 and 7 days of treatment. The American Journal of Gastroenterology. 95(9). 2434–2435. 2 indexed citations

19.

Sloan, Sheldon, Alfred Rademaker, & Peter J. Kahrilas. (1992). Determinants of Gastroesophageal Junction Incompetence: Hiatal Hernia, Lower Esophageal Sphincter, or Both?. Annals of Internal Medicine. 117(12). 977–982. 203 indexed citations

20.

Sloan, Sheldon & Peter J. Kahrilas. (1991). Impairment of esophageal emptying with hiatal hernia. Gastroenterology. 100(3). 596–605. 208 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact